Answers
#1 in Business Subscribe Email Print

You are here: Home > Business > PR > Publicity - What to Say to a Reporter

Tags

  • would
  • going
  • tackle
  • developing combination
  • developing combination
  • developing combination

  • Links

  • Relationships: Do You Have Trouble Saying No?
  • The Importance Of Customer Service in Your Home Business
  • Relationship Advice - A is for Availability
  • Answers - Publicity - What to Say to a Reporter

    You can have dozens of marvelous ideas to get free publicity, bu
    According to USFDA, a combination product is one composed of any combination of a drug and device; biological product and device; drug and biological product
    t nothing will happen unless you pick up the phone and call a re
    ; or drug, device, and biological product and fixed dose combination would include two or more combinations of drug.

    Examples of combination products may in
    porter.

    Here's where the publicity game gets interesting for ma
    lude drug-coated devices, drugs packaged with delivery devices in medical kits, and drugs and devices packaged separately but intended to be used together.

    rketing-minded financial planners. You’ve been tracking reporter
    here is enormous increase in the number of combination products entering the market in the recent years. Combination products have proven advantages but fixe
    s – you know who covers your topics. You’ve been tracking Topic
    d dose combinations are still in the process of convincing regulatory authority on their advantages over the single ingredient formulations.

    Combination pro
    A’s and trends affecting your market. You’re ready!

    When you ca
    ucts have become life saving products for the pharmaceutical companies who doesn’t have many innovative molecules in their product pipeline and have been inc
    ll a reporter, you’re going to say something like:

    "Hi, Bob. I’
    easingly used in the product life cycle management. Even the companies having product patents are trying to extend their product life cycle through the combi
    m Stephanie Smart, and I am a financial planning consultant in t
    nation products and maximize the revenues. But the companies involved in this practice are overlooking that they are burdening the patients both economically
    own. I see you cover mutual funds, and I thought you might be in
    and physically. They need to rightly judge the benefits of the combination products and they have to even look at the risks involved when combining the produ
    terested in this.

    Did you know that about two-thirds of my clie
    ts. Some of the combination products were well accepted by physicians while others suffered. Companies involved in development of combination products are fi
    nts lately have been asking me for help with picking the right i
    ding difficulty in defining their combination products and facing various challenges from selecting a combination to marketing it.

    Following aspects would a
    ndex fund? It’s a fascinating switch from what I’ve been seeing
    dd to the challenges in developing combination products:

    Which markets to tap where the combination products can do fairly well?
    Which combination prod
    in the past."

    And it has broad implications for our community,
    cts are meaningful and rational?
    Which therapeutic categories to select?
    Which Combinations can address unmet needs of the patients?
    Do combin
    given the number of young professionals in the area, just beginn
    tions increase the patient compliance?
    What would be the developing cost?
    How to tackle the risks encountered during combination product developmen
    ing to think about retirement planning."

    Or… “Bob, I saw your s
    t?

    As combination products don't fit into the traditional categories of drugs, medical devices, or biological products, the USFDA is in the process of devel
    tory last week on retirement planning by young professionals. Di
    ping new procedures for reviewing their safety, efficacy and quality.

    Professional from academic institutions, pharmaceutical industries, health care indust
    d you know that these folks are already leaning more towards ind
    y and representatives from various regulatory agencies are working out to design the regulatory requirements for manufacture and sale of combination products
    ex funds than traditional mutual funds? Would you like to know m
    .

    As there is an increasing trend of the combination products companies manufacturing such products should be able to tackle the problems involved in the de
    ore?”

    Trust me, every mutual fund reporter worth his or her wei
    elopment. They need to be wiser in analyzing the market trends and the regulatory requirements.

    Companies that provide selfless information through particip
    ght in stock certificates is going to listen very closely to you


    tion in industry events and feedback to regulatory authorities would be able to face the challenges and will be successful in developing combination products

    HTTP = HTML link (for blogs, profiles,phorums):
    <a href="http://www.answers.org.ua/article/34011/answers-Publicity--What-to-Say-to-a-Reporter.html">Publicity - What to Say to a Reporter</a>

    BB link (for phorums):
    [url=http://www.answers.org.ua/article/34011/answers-Publicity--What-to-Say-to-a-Reporter.html]Publicity - What to Say to a Reporter[/url]

    Related Articles:

    Brand Image - Brand Identity - Brand Strategy - Brand Identity Guru

    Commense GED

    10 Sure Fire Strategies for Career Fair Success

    Bookmark it: del.icio.us digg.com reddit.com netvouz.com google.com yahoo.com technorati.com furl.net bloglines.com socialdust.com ma.gnolia.com newsvine.com slashdot.org simpy.com shadows.com blinklist.com